Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383 | 0.75 | — | — | |
| SCHEMBL360281 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL11081569 | 0.73 | LPAR2 (0.33) | LPAR2LPAR3TSHR | |
| Ammonia Solution, Strong SCHEMBL6676854 | 0.73 | LPAR2 (0.33) | LPAR2LPAR3TSHR | |
| Ammonia Solution, Strong SCHEMBL2540910 | 0.73 | — | — | |
| Phosphoric Acid SCHEMBL10534010 | 0.73 | KDM4E (0.37) | LPAR2LPAR3TSHR | |
| SCHEMBL2543714 | 0.73 | — | — | |
| Charcoal, Activated SCHEMBL526932 | 0.73 | — | — | |
| SCHEMBL2538056 | 0.73 | — | — | |
| SCHEMBL2542186 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305314-A2 | Remodelling and glycoconjugation of antibodies | BioGeneriX AG (DE) | 2011-04-06 | — | — | EP | claimed |
| EP-2292271-A2 | Remodelling and glycoconjugation of an antibody | BioGeneriX AG (DE) | 2011-03-09 | — | — | EP | claimed |
| US-5869471-A | Methods for the treatment of arthritis using phosphonates and NSAIDS | THE PROCTOR & GAMBLE COMPANY (US) | 1999-02-09 | — | — | US | claimed |
| EP-0648120-B1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMA (US) | 1997-12-29 | — | — | EP | claimed |
| US-5616560-A | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone | THE PROCTER & GAMBLE COMPANY (US) | 1997-04-01 | — | — | US | claimed |
| EP-0650361-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-05-03 | — | — | EP | claimed |
| EP-0648120-A1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-04-19 | — | — | EP | claimed |
| EP-0618805-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BISPHOSPHONATES AND PARATHYROID HORMONE | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-10-12 | — | — | EP | claimed |
| WO-1994000129-A1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| WO-1994000130-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| WO-1993011786-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BISPHOSPHONATES AND PARATHYROID HORMONE | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-06-24 | — | — | WO | claimed |
| WO-2024116120-A1 | MATRICES FOR WOUND HEALING | REGENICS AS (NO) | 2024-06-06 | — | — | WO | disclosed |
| US-20210379118-A1 | USE OF EGG CELLULAR EXTRACT FOR WOUND HEALING | REGENICS AS (NO) | 2021-12-09 | — | — | US | disclosed |
| US-11007385-B2 | Use of cellular extracts for skin rejuvenation | REGENICS AS (NO) | 2021-05-18 | — | — | US | disclosed |
| EP-3459522-B1 | USE OF EGG CELLULAR EXTRACTS FOR WOUND TREATMENT | REGENICS AS (NO) | 2021-02-17 | — | — | EP | disclosed |
| US-4963681-A | Process for synthesis of aminomethylene phosphonoalkylphosphinates | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0298553-A1 | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | Norwich Eaton Pharmaceuticals, Inc. (US) | 1989-01-11 | — | — | EP | disclosed |
| EP-0298553-A1 | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | Norwich Eaton Pharmaceuticals, Inc. (US) | 1989-01-11 | — | — | EP | disclosed |
| EP-0298555-A1 | Process for synthesis of aminomethylene phosphonoalkylphosphinates | Norwich Eaton Pharmaceuticals, Inc. (US) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007385-B2 | Use of cellular extracts for skin rejuvenation | MMP8, COL14A1, GLA | LPAR2 723/4885LPAR3 522/4885TSHR 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.